Continuous Glucose Monitoring in Neonatal Hyperinsulinism
NCT ID: NCT06363929
Last Updated: 2025-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
1 participants
OBSERVATIONAL
2023-06-01
2025-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CGM Use in Preterm Infants
NCT05436925
Continuous Glucose Monitoring in Infants
NCT04458649
Continuous Glucose Monitoring in HIE
NCT06563687
Performance of the Dexcom G6 Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
NCT03935191
Continuous Glucose Monitoring in At-Risk Newborns
NCT04386005
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neonates with hyperinsulinism
Neonates with a diagnosis of hyperinsulinism will wear a Dexcom G6 continuous glucose monitor placed for 10 days.
Dexcom G6 continuous glucose monitor
Dexcom G6 continuous glucose monitor to be placed on neonates with hyperinsulinism for 10 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexcom G6 continuous glucose monitor
Dexcom G6 continuous glucose monitor to be placed on neonates with hyperinsulinism for 10 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational Age: \> 28 weeks gestational age
* Diagnosis of hyperinsulinism based on critical sample and/or glucagon challenge
Exclusion Criteria
* Infants colonized or infected with multi-drug resistant organisms (i.e. MRSA, VRE, ESBL producing bacteria)
* Infants on hypothermic protocols
* Infants expected to remain in the NICU \<24 hours
* Infants enrolled in a competing clinical trial
* Family/team have decided to limit or redirect from aggressive NICU technological support
* Ward of the state
24 Hours
3 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DexCom, Inc.
INDUSTRY
MemorialCare Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erin L Okawa, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Health Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Miller Children's Hospital
Long Beach, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
341-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.